From Medical News Today. Time will tell if this is a useful marker in the clinical setting in prostate cancer. What I find most interesting about the press release is the statement about expected "launch of a series of additional algorithms to serve the pathology and research communities".
"BioImagene, the leading provider of innovative digital pathology solutions announced the launch of a new Ki-67 prostate image analysis algorithm. The algorithm, which is part of Virtuoso TM, a comprehensive suite of web-based software applications for digital pathology, is used to detect and provide quantitative measurement of the protein biomarker Ki-67.
According to the Journal of Clinical Oncology, Cancer Research and other clinical journals, Ki-67 immunohistochemistry may be a valuable predictor of biochemical relapse and distant metastasis after prostatectomy and radiation therapy. Prostate cancer continues to be the most prevalent cancer in men, according to the American Cancer Society.
"The launch of the Ki-67 algorithm that can be used in a research setting illustrates the potential impact digital pathology can have on the practice of medicine," commented Dr. Ajit Singh, CEO BioImagene. "In the coming months, we expect to launch a series of additional algorithms to serve the pathology and research communities."
The launch of the Ki-67 algorithm adds to the company's growing offering of image analysis tools. BioImagene also has a PIN4 algorithm for prostate cancer research, and FDA cleared algorithms to assess HER2/neu immunohistochemistry status. The iScan Coreo and associated software are used to detect and provide a quantitative measurement of HER2/neu, a protein measured in breast cancer patients to determine their candidacy for treatment with the Genentech drug Herceptin™."